Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children

References

• ChamberlainMCTemozolomide: therapeutic limitations in the treatment of adult high-grade gliomasExpert Rev Neurother2010101537154420925470
   PubMed Web of Science ®Google Scholar
• HeimbergerABSampsonJHImmunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Neuro Oncol20111331321149252
   PubMed Web of Science ®Google Scholar
• GuzhovaIVShevtsovMAAbkinSVPankratovaKMMargulisBAIntracellular and extracellular Hsp70 chaperone as a target for cancer therapyInt J Hyperthermia20132939940823845032
   PubMed Web of Science ®Google Scholar
• SrivastavaPInteraction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responsesAnnu Rev Immunol20022039542511861608
   PubMed Web of Science ®Google Scholar
• CalderwoodSKTheriaultJRGongJMessage in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunityEur J Immunol2005352518252716144035
   PubMed Web of Science ®Google Scholar
• SrivastavaPKCallahanMKMauriMMTreating human cancers with heat shock protein-peptide complexes: the road aheadExpert Opin Biol Ther2009917918619236248
   PubMed Web of Science ®Google Scholar
• WoodCSrivastavaPBukowskiRAn adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open-label, randomized phase III trialLancet200837214515418602688
   PubMed Web of Science ®Google Scholar
• TestoriARichardsJWhitmanEPhase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study GroupJ Clin Oncol20082695596218281670
   PubMed Web of Science ®Google Scholar
• MambulaSSStevensonMAOgawaKCalderwoodSKMechanisms for Hsp70 secretion: crossing membranes without a leaderMethods20074316817517920512
   PubMed Web of Science ®Google Scholar
• AseaAInitiation of the immune response by extracellular Hsp72: chaperokine activity of Hsp72Curr Immunol Rev2006220921517502920
   PubMedGoogle Scholar
• AseaARehliMKabinguENovel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR)2 and TLR4J Biol Chem2008277150281503411836257
   PubMed Web of Science ®Google Scholar
• VabulasRMAhmad-NejadPda CostaCEndocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cellsJ Biol Chem2001276313323133911402040
   PubMed Web of Science ®Google Scholar
• GastparRGehrmannMBauseroMAHeat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cellsCancer Res2005655238524715958569
   PubMed Web of Science ®Google Scholar
• AbkinSVPankratovaKMKomarovaEYGuzhovaIVMargulisBAHsp70 chaperone-based gel composition as a novel immunotherapeutic antitumor toolCell Stress Chaperones20131839139623233202
   PubMed Web of Science ®Google Scholar
• ShevtsovMAPozdnyakovAVMikrinaALEffective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70Int J Cancer Epub2014319
   Web of Science ®Google Scholar
• GuzhovaIVKomarovaEYPimenovaAABakhtinYBKaminskaiaEVMargulisBAThe role of extracellular chaperone Hsp70 in creating antitumor immunity in rat rhabdomyosarcoma RA-2 modelVopr Onkol200854611617 Russian19069476
   PubMedGoogle Scholar
• ShevtsovMAKomarovaEYMeshalkinaDAExogenously delivered heat shock protein 70 displaces its endogenous analog and sensitizes cancer cells to lymphocytes-mediated cytotoxicityOncotarget Epub2014322
   Google Scholar
• GuzhovaIVLazarevVFKaznacheevaAVNovel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of Huntington diseaseHum Mol Genet2011203953396321775503
   PubMed Web of Science ®Google Scholar
• RF Patent Application. Number 2013128880 from June 25, 2013; number 2013140067 from August 28, 2013
   Google Scholar
• National Cancer Institute, National Institutes of Health2003Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, June 10, 2003 update Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40Accessed May 15, 2014
   Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomasJ Clin Oncol19908127712802358840
   PubMed Web of Science ®Google Scholar
• YamanakaRHommaJYajimaNClinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trialClin Cancer Res2005114160416715930352
   PubMed Web of Science ®Google Scholar
• FyfeGFisherRIRosenbergSASznolMParkinsonDRLouieACResults of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyJ Clin Oncol1995136886967884429
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangYCTopalianSLTreatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2JAMA19942719079138120958
   PubMed Web of Science ®Google Scholar
• GogasHIoannovichJDafniUPrognostic significance of autoimmunity during treatment of melanoma with interferonN Engl J Med200635470971816481638
   PubMed Web of Science ®Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol1996147178558223
   PubMed Web of Science ®Google Scholar
• SpitlerLEGrossbardMLErnstoffMSAdjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factorJ Clin Oncol2000181614162110764421
   PubMed Web of Science ®Google Scholar
• WattersJJSchartnerJMBadieBMicroglia function in brain tumorsJ Neurosci Res20058144745515959903
   PubMed Web of Science ®Google Scholar
• KimREmiMTanabeKCancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunityImmunology200611925426417005005
   PubMed Web of Science ®Google Scholar
• KennedyBCMaierLMD’AmicoRDynamics of central and peripheral immunomodulation in a murine glioma modelBMC Immunol2009101119226468
   PubMed Web of Science ®Google Scholar
• BaitschLBaumgaertnerPDevevreEExhaustion of tumor-specific CD8+ T cells in metastases from melanoma patientsJ Clin Invest20111212350236021555851
   PubMed Web of Science ®Google Scholar
• YiJSCoxMAZajacAJT cell exhaustion: characteristics, causes and conversionImmunology201012947448120201977
   PubMed Web of Science ®Google Scholar
• KimPSAhmedRFeatures of responding T cells in cancer and chronic infectionCurr Opin Immunol20102222323020207527
   PubMed Web of Science ®Google Scholar
• GengHZhangGMXiaoHHSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanomaInt J Cancer20061182657266416425224
   PubMed Web of Science ®Google Scholar
• MarincolaFJaffeeEHicklinDFerroneSEscape of human solid tumors from T cell recognition: molecular mechanisms and functional significanceAdv Immunol20007418127310605607
   PubMedGoogle Scholar
• DisisMLImmune regulation of cancerJ Clin Oncol2010284531453820516428
   PubMed Web of Science ®Google Scholar
• ArlenPGulleyJPSkarupaCLA randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerClin Cancer Res2006121260126916489082
   PubMed Web of Science ®Google Scholar
• WeihrauchMAnsenSJurkiewiczEPhase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancerClin Cancer Res2005155993600116115944
   PubMed Web of Science ®Google Scholar
• GribbenJRyanDBoyajianRUnexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyClin Cancer Res2005114430443615958627
   PubMed Web of Science ®Google Scholar
• NowakARobinsonBLakeRSynergy between chemotherapy and immunotherapy in the treatment of established murine solid tumorsCancer Res2003634490449612907622
   PubMed Web of Science ®Google Scholar
• CasaresNPequignotNTesniereACaspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJ Exp Med20062021691170116365148
   PubMed Web of Science ®Google Scholar
• ShevtsovMAGuzhovaIVMargulisBAThe hypothesis of a mechanism of anti-tumor action of heat shock protein Hsp70 Available from: http://www.cytokines.ru/english/2013/1/Art6.phpAccessed May 21, 2014
   Google Scholar
• ShevtsovMAShatikSVTokarevAVBiodistribution of the recombinant heat shock protein rhHsp70 in intracranial C6 glioma model in Wistar rats and subcutaneous B16/F10 melanoma in C57BL/6 miceVopr Onkol2013597883 Russian23814854
   PubMedGoogle Scholar
• ShevtsovMAYakovlevaLYNikolaevBPTumor targeting using magnetic nanoparticle Hsp70 conjugate in the model of the C6 gliomaNeuro Oncol201416384924305705
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience20063131960196417008531
   PubMed Web of Science ®Google Scholar
• DonsonAMBirksDKBartonVNImmune gene and cell enrichment is associated with a good prognosis in ependymomaJ Immunol20091837428744019917695
   PubMed Web of Science ®Google Scholar
• CraneCAHanSJAhnBIndividual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone proteinClin Cancer Res20131920521422872572
   PubMed Web of Science ®Google Scholar
• PillaLPatuzzoRRivoltiniLA phase II trial of vaccination with autologous, tumor-derived heat shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsCancer Immunol Immunother200655953968
   Web of Science ®Google Scholar
• MassaCMelaniCColomboMPChaperon and adjuvant activity of Hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigensCancer Res2005657942794916140966
   PubMed Web of Science ®Google Scholar
• ZengYChenXLarmonierNNatural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccinationInt J Cancer20061192624263116989012
   PubMed Web of Science ®Google Scholar
• KnutsonKLDisisMLSalazarLGCD4 regulatory T cells in human cancer pathogenesisCancer Immunol Immunother20075627128516819631
   PubMed Web of Science ®Google Scholar
• LiMOFlavellRAContextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10Immunity20082846847618400189
   PubMed Web of Science ®Google Scholar
• CurielTJCoukosGZouLSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med20041094294915322536
   PubMed Web of Science ®Google Scholar
• DannullJSuZRizzieriDEnhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJ Clin Invest20051153623363316308572
   PubMed Web of Science ®Google Scholar
• MorseMAHobeikaACOsadaTDepletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccinesBlood200811261061818519811
   PubMed Web of Science ®Google Scholar
• RolleCESenguptaSLesniakMSChallenges in clinical design of immunotherapy trials for malignant gliomaNeurosurg Clin N Am20102120121419944979
   PubMed Web of Science ®Google Scholar
• DisisMLSchiffmanKGooleyTAMcNeelDGRinnKKnutsonKLDelayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunizationClin Cancer Res200061347135010778962
   PubMed Web of Science ®Google Scholar